Effect of discontinuing immune-modulating drugs versus control group on prognosis in patients with relapsing-remitting multiple sclerosis
Phase 3
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20120215009014N516
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 178
Inclusion Criteria
Age 55 to 80 years
Relapsing-remitting multiple sclerosis
Taking drugs that modulate the immune system
Exclusion Criteria
Disease attack in the last 5 years
Taking Tysabri or Fingolimod drugs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method